共 50 条
- [31] Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk FeaturesBLOOD, 2020, 136Gutman, Jonathan A.Winters, AmandaAmaya, Maria L.McMahon, Christine M.Schowinsky, JeffreyAbbott, DianaHammes, AndrewPei, ShanshanStevens, Brett M.Jordan, Craig T.Smith, ClaytonPollyea, Daniel A.
- [32] Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Ravandi, FarhadCarraway, Hetty E.Taningco, LiliaLaille, EricGong, JingPrebet, ThomasDe Menezes, Daniel LopesWei, Andrew H.
- [33] Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemiaHAEMATOLOGICA, 2023, 108 (07) : 1965 - 1967Ramdohr, FlorianHennings, RobertMonecke, AstridKayser, Sabine
- [34] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S256Jaddaoui, SamihaBencharef, HanaaAddakiri, SaraDehbi, HindLamchahab, MounaQuessar, AsmaaMadani, AbdellahOukkache, Bouchra
- [35] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S255Zeidan, Amer M.Westermann, JoergKovacsovics, TiborAssouline, SaritSchuh, Andre C.Kim, Hee-JeMacias, Gabriela RodriguezSanford, DavidLuskin, Marlise R.Stein, Eytan M.Malek, KamelLyu, JiayingStegert, MarioEsteve, Jordi
- [36] Evaluation of Lymphocyte Immunity in Patients Treated with Venetoclax-Azacitidine for Acute Myeloid LeukemiaBLOOD, 2024, 144 : 6061 - 6062Kanaya, MinoruSuzuki, TomaKajikawa, SayakaYokoyama, EmiIzumiyama, KohSaito, MakotoMorioka, MasanobuMori, AkioMatsukawa, ToshihiroOnozawa, MasahiroTeshima, TakanoriKondo, Takeshi
- [37] Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility AnalysisCURRENT ONCOLOGY, 2022, 29 (10) : 7524 - 7536Guinan, KimberlyMathurin, KarineAu, YunghanSchuh, Andre C.Bui, Cat N.Chai, XingleiLachaine, Jean
- [38] Venetoclax and Posaconazole Plus Standard Dose Cytarabine or Azacytidine for Newly Diagnosed Acute Myeloid LeukemiaBLOOD, 2020, 136Tran-Der TanChiou, Lun-Wei
- [39] Unmodified Dose of Azacitidine Plus Venetoclax Regimen without Drug Interactions during the First Cycle Leads to Similar Outcomes between Viale-a Clinical Trial and Real-Life in Acute Myeloid LeukemiaBLOOD, 2022, 140 : 11718 - 11719Sedaki, BochraIat, AlexandreLoschi, MichaelBenachour, SamiChiche, EdmondRyffel, LeaBrugel, PatriciaSudaka, IsabelleAquaronne, DanieleFerrero, CorinneDadone, BerengereCluzeau, Thomas
- [40] Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (33) : 3848 - +Kadia, Tapan M.Reville, Patrick K.Wang, XuemeiRausch, Caitlin R.Borthakur, GautamPemmaraju, NaveenDaver, Naval G. G.DiNardo, Courtney D. D.Sasaki, KojiIssa, Ghayas C. C.Ohanian, MaroMontalban-Bravo, GuillermoShort, Nicholas J. J.Jain, NitinFerrajoli, AlessandraBhalla, Kapil N. N.Jabbour, EliasTakahashi, KoichiMalla, RashmiQuagliato, KellyKanagal-Shamanna, RashmiPopat, Uday R. R.Andreeff, MichaelGarcia-Manero, GuillermoKonopleva, Marina Y. Y.Ravandi, FarhadKantarjian, Hagop M. M.